carfilzomib; multiple myeloma; proteasome inhibitor; real world; relapsed/refractory
Abstract :
[en] This prospective, observational study examined the real-world use of carfilzomib across 11 European countries in adults with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line of therapy. Carfilzomib and dexamethasone (Kd) use, effectiveness and safety were analyzed. In total, 271 patients received Kd among 701 adults enrolled. The median relative dose intensity of carfilzomib was 82.7% (20/56 mg/m(2), twice weekly). The overall response rate (ORR) to Kd was 68.8% (95% confidence interval [CI], 62.7-74.5): 79.2% in second line (2L), 71.6% in third line (3L) and 63.1% in fourth line or later (4L+). The ORR was 59.9% (95% CI, 51.1-68.1) in the lenalidomide-refractory subgroup and 67.7% (95% CI, 48.6-83.3) in the not lenalidomide-refractory subgroup. In the anti-CD38 refractory subgroup, the ORR was 51.6% (95% CI, 38.6-64.5); ORRs were higher when Kd was received at 2L/3L (66.7%) than at 4L+ (49.1%). Overall, patients were treated for a median time of 7.7 months. One-fifth of patients reported treatment-related treatment-emergent adverse events (≥grade 3), with a safety profile consistent with previous clinical trials. This study demonstrated the real-world use, effectiveness and safety of Kd in patients with RRMM. Despite the increasing number of new therapeutic strategies to treat RRMM, Kd remains a safe and effective option, even for older, frail and lenalidomide- or anti-CD38 mAb-refractory patients.
Disciplines :
Hematology
Author, co-author :
Terpos, Evangelos ; Department of Clinical Therapeutics, School of Medicine, National and
Zambello, Renato ; Hematology and Clinical Immunology Branch, Department of Medicine, University of
Leleu, Xavier; Department of Hematology, University Hospital Center La Miletrie and Inserm, CIC
Kuehr, Thomas; Department of Internal Medicine IV, Academic Teaching Hospital Wels-Grieskirchen,
Badelita, Sorina N; Fundeni Clinical Institute, 72437 Bucharest, Romania.
Katodritou, Eirini ; Department of Hematology, Theagenio Cancer Hospital, 54007 Thessaloniki, Greece.
Dimopoulos M.A. Moreau P. Terpos E. Mateos M.-V. Zweegman S. Cook G. Delforge M. Hájek R. Schjesvold F. Cavo M. et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up HemaSphere 2021 32 309 322
Gandhi U.H. Cornell R.F. Lakshman A. Gahvari Z.J. McGehee E. Jagosky M.H. Gupta R. Varnado W. Fiala M.A. Chhabra S. et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy Leukemia 2019 33 2266 2275 10.1038/s41375-019-0435-7 30858549
Usmani S.Z. Hoering A. Cavo M. Miguel J.S. Goldschimdt H. Hajek R. Turesson I. Lahuerta J.J. Attal M. Barlogie B. et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma—An IMWG Research Project Blood Cancer J. 2018 8 123 10.1038/s41408-018-0155-7 30470751
Moreau P. Richardson P.G. Cavo M. Orlowski R.Z. San Miguel J.F. Palumbo A. Harousseau J.L. Proteasome inhibitors in multiple myeloma: 10 years later Blood 2012 120 947 959 10.1182/blood-2012-04-403733 22645181
Mikhael J. Treatment options for triple-class refractory multiple myeloma Clin. Lymphoma Myeloma Leuk. 2020 20 1 7 10.1016/j.clml.2019.09.621
McBride A. Klaus J.O. Stockerl-Goldstein K. Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma Am. J. Health Syst. Pharm. 2015 72 353 360 10.2146/ajhp130281
European Medicines Agency (EMA) Kyprolis—Product Information Available online: https://www.ema.europa.eu/en/documents/product-information/kyprolis-epar-product-information_en.pdf (accessed on 5 July 2022)
Dimopoulos M. Wang M. Maisnar V. Minarik J. Bensinger W. Mateos M.V. Obreja M. Blaedel J. Moreau P. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study J. Hematol. Oncol. 2018 11 49 10.1186/s13045-018-0583-7
Dimopoulos M.A. Moreau P. Palumbo A. Joshua D. Pour L. Hájek R. Facon T. Ludwig H. Oriol A. Goldschmidt H. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study Lancet Oncol. 2016 17 27 38 10.1016/S1470-2045(15)00464-7
Dimopoulos M. Quach H. Mateos M.V. Landgren O. Leleu X. Siegel D. Weisel K. Yang H. Klippel Z. Zahlten-Kumeli A. et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study Lancet 2020 396 186 197 10.1016/S0140-6736(20)30734-0
Blonde L. Khunti K. Harris S.B. Meizinger C. Skolnik N.S. Interpretation and impact of real-world clinical data for the practicing clinician Adv. Ther. 2018 35 1763 1774 10.1007/s12325-018-0805-y
Facon T. Dimopoulos M.A. Meuleman N. Belch A. Mohty M. Chen W.M. Kim K. Zamagni E. Rodriguez-Otero P. Renwick W. et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial Leukemia 2020 34 224 233 10.1038/s41375-019-0539-0 31427722
Greipp P.R. Miguel J.S. Durie B.G. Crowley J.J. Barlogie B. Bladé J. Boccadoro M. Child J.A. Avet-Loiseau H. Kyle R.A. International staging system for multiple myeloma J. Clin. Oncol. 2005 23 3412 3420 10.1200/JCO.2005.04.242 15809451
Rajkumar S.V. Harousseau J.-L. Durie B. Anderson K.C. Dimopoulos M. Kyle R. Blade J. Richardson P. Orlowski R. Siegel D. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1 Blood 2011 117 4691 4695 10.1182/blood-2010-10-299487
Clopper C.J. Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 1934 26 404 413 10.1093/biomet/26.4.404
Schemper M. Smith T.L. A note on quantifying follow-up in studies of failure time Control. Clin. Trials 1996 17 343 346 10.1016/0197-2456(96)00075-X
European Medicines Agency (EMA) Neofordex—Product Information Available online: https://www.ema.europa.eu/en/documents/product-information/neofordex-epar-product-information_en.pdf (accessed on 5 July 2022)
Moreau P. Joshua D. Chng W.J. Palumbo A. Goldschmidt H. Hájek R. Facon T. Ludwig H. Pour L. Niesvizky R. et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs. bortezomib and dexamethasone in the phase 3 ENDEAVOR study Leukemia 2017 31 115 122 10.1038/leu.2016.186
Facon T. Niesvizky R. Mateos M.-V. Siegel D. Rosenbaum C. Bringhen S. Weisel K. Ho P.J. Ludwig H. Kumar S. et al. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma Blood Adv. 2020 4 5449 5459 10.1182/bloodadvances.2020001965
Terpos E. Slama B. Zambello R. Bedelita S.N. Katodritou E. Caers J. Kühr T. Suzan F. Mohammad A. Wetten S. et al. Real-world evidence of the use of carfilzomib among multiple myeloma patients with at least one prior therapy across 10 European countries and Israel Blood 2020 136 38 39 10.1182/blood-2020-134475
Dimopoulos M.A. Goldschmidt H. Niesvizky R. Joshua D. Chng W.J. Oriol A. Orlowski R.Z. Ludwig H. Facon T. Hajek R. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial Lancet Oncol. 2017 18 1327 1337 10.1016/S1470-2045(17)30578-8
Chari A. Romanus D. Palumbo A. Blazer M. Farrelly E. Raju A. Huang H. Richardson P. Randomized clinical trial representativeness and outcomes in real-world patients: Comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma Clin. Lymphoma Myeloma Leuk. 2020 20 8 17.e16 10.1016/j.clml.2019.09.625
Del Giudice M.L. Gozzetti A. Antonioli E. Attucci I. Pengue L. Cassano Cassano R. Ghio F. Orciuolo E. Simoncelli M. Bocchia M. et al. Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational study Eur. J. Haematol. 2022 109 373 380 10.1111/ejh.13819 35749094
Kawasaki A. Murakami H. Chou T. Matsushita M. Kizaki M. Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma Future Oncol. 2022 18 2661 2674 10.2217/fon-2022-0259 35815645
Cavo M. Terpos E. Bargay J. Einsele H. Cavet J. Greil R. de Wit E. The multiple myeloma treatment landscape: International guideline recommendations and clinical practice in Europe Expert Rev. Hematol. 2018 11 219 237 10.1080/17474086.2018.1437345 29415570
Goldschmidt H. Ashcroft J. Szabo Z. Garderet L. Navigating the treatment landscape in multiple myeloma: Which combinations to use and when? Ann. Hematol. 2019 98 1 18 10.1007/s00277-018-3546-8
Moreau P. Kumar S.K. San Miguel J. Davies F. Zamagni E. Bahlis N. Ludwig H. Mikhael J. Terpos E. Schjesvold F. Treatment of relapsed and refractory multiple myeloma: Recommendations from the International Myeloma Working Group Lancet Oncol. 2021 22 e105 e118 10.1016/S1470-2045(20)30756-7
European Medicines Agency (EMA) Darzalex—Product Information Available online: https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf (accessed on 20 October 2022)
Moreau P. Kumar S. Boccia R. Iida S. Goldschmidt H. Cocks K. Trigg A. Zahlten-Kumeli A. Yucel E. Panjabi S.S. et al. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study) Leukemia 2019 33 2934 2946 10.1038/s41375-019-0480-2
Leleu X. Katodritou E. Kuehr T. Terpos E. Caers J. Zambello R. Brescianini A. Liang T. Wetten W. Badelita S.N. Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel eJHaem 2022 in press
Cohen Y. Spicka I. Maisnar V. Simeonova K. Björklöf K. Iordan A. Ianakieva V. Badelita S.N. Real-world evidence of carfilzomib use among multiple myeloma patients with at least one prior therapy across 4 countries in Central Eastern Europe and Israel HemaSphere 2021 5 (Suppl. 2) 781 782 10.1097/HS9.0000000000000566
